Protia Inc. (KOSDAQ:303360)

Market Cap	51.12B
Revenue (ttm)	12.43B
Net Income (ttm)	2.86B
Shares Out	12.88M
EPS (ttm)	222.60
PE Ratio	17.84
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,021
Average Volume	400,968
Open	3,805.00
Previous Close	3,850.00
Day's Range	3,805.00 - 4,065.00
52-Week Range	2,430.00 - 4,360.00
Beta	0.08
RSI	61.03
Earnings Date	n/a

About Protia

Protia Inc. designs, develops, and sells diagnostic kits in South Korea. The company offers PROTIA Allergy-Q, an assay kit for quantitative determination of specific IgE antibodies against individual allergens in human serum using immunoblotting technique; ImmuneCheck IgG, a whole blood test kit for total IgG concentration measurement; and TriCheck-C, an in vitro diagnostic kit for the qualitative test of human chorionic gonadotropin in human urine samples for the pregnancy diagnosis. It also provides protia food iga, a chronic food intolerance...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 303360

Financial Performance

In 2024, Protia's revenue was 10.51 billion, an increase of 27.79% compared to the previous year's 8.23 billion. Earnings were 2.44 billion, an increase of 427.52%.